We are live on
!
Find out more
MCL
MWG Caph Ltd Portfolio holdings
AUM
$72.4M
This Fund
S&P 500
This Quarter
Est. Return
+42.08%
1 Year Est. Return
–
3 Year Est. Return
–
5 Year Est. Return
–
10 Year Est. Return
–
AUM
$72.4M
AUM Growth
–
Cap. Flow
+$62.9M
Cap. Flow
% of AUM
86.86%
Top 10 Holdings %
Top 10 Hldgs %
100%
Holding
3
New
3
Increased
–
Reduced
–
Closed
–
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
Beam Therapeutics
BEAM
|
+$32.3M |
| 2 |
Lyell Immunopharma
LYEL
|
+$22.6M |
| 3 |
Prime Medicine
PRME
|
+$7.97M |
Top Sells
No sells this quarter
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Healthcare | 100% |
Similar funds
IA
YCM
BBW
QEI
RWA
KWM
RRCP
BCPEMI
MWG Caph Ltd's Q4 2025 Portfolio in Review
Q4 2025 is the first quarter with a 13F filing on record for MWG Caph Ltd, which disclosed 3 positions worth $72.4M. Its ten largest holdings account for 100% of the portfolio.
Its largest position is Beam Therapeutics: 1,266,934 shares worth $35.1M.
By sector, the portfolio is most concentrated in Healthcare at 100% of assets.
- MWG Caph Ltd's largest Q4 2025 buy was Beam Therapeutics: 1,266,934 shares worth $35.1M.
- MWG Caph Ltd's ten largest holdings make up 100% of its $72.4M portfolio in Q4 2025.
- MWG Caph Ltd disclosed 3 positions in Q4 2025, its first 13F filing on record.
Based on MWG Caph Ltd's 13F filing for Q4 2025, filed 17 Feb 2026.